Would this help CPSP(Central post-stroke pain)? Or will the word marijauna cause your doctor to reject even trying this?
New Study Analyzes Cost Effectiveness of Smoked Cannabis to Treat Chronic Neuropathic Pain
FOR IMMEDIATE RELEASE
FROM MARY ANN LIEBERT, INC., PUBLISHERS
New Rochelle, NY, January 29, 2019—Smoked cannabis as an
adjunctive second-line therapy to treat chronic peripheral neuropathy
can be both effective and cost-effective. The results of a new study
simulating its use in one million patients are published in Cannabis and Cannabinoid Research, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here to read the full-text article free on the Cannabis and Cannabinoid Research website.
In the article entitled “A Cost-Effectiveness Model for Adjunctive Smoked Cannabis in the Treatment of Chronic Neuropathic Pain,” David Grelotti, MD,
University of California San Diego (La Jolla) and coauthors from UCSD,
University of California Center for Medicinal Cannabis Research (San
Diego), and Columbia University (New York, NY) created a computer
simulation to compare the cost of usual first-, second-, and third-line
care with those supplemented with smoked cannabis. They modeled efficacy
and adverse events based on clinical trial and other existing study
data, and derived cannabis cost from retail market pricing.
“With the opioid crisis continuing unabated, it is essential to
understand whether cannabis might offer a safe, effective, and
economically sound approach to pain management. This article offers new
data that will help evaluate this possibility,” says Editor-in-Chief Daniele Piomelli, PhD, PharmD, University of California-Irvine, School of Medicine.
Research reported in this publication was supported by the National
Institutes of Health under Award Number 1TL1TR001443. The content is
solely the responsibility of the authors and does not necessarily
represent the official views of the National Institutes of Health.
No comments:
Post a Comment